Wenhua Wang

As the ADC field shifts to novel payload mechanisms and more complex ADC design to deliver meaningful patient impact, quality characterization and control strategies need to be adapted and updated to keep up with the rate of ADC innovation.

Join this workshop led by big pharma leaders and members of the IQ consortium to investigate best approaches for non-cytotoxic and non-traditional ADC control strategies.

Workshop highlights include:

• Defining the control strategy for noncytotoxic bioconjugates including AOCs and antibody–peptide conjugates across CQAs, release testing, and stability
• Comparing control strategies for noncytotoxic versus cytotoxic bioconjugates, highlighting differences in potency assays, impurity profiles, and safety controls
• Applying patient centric quality control to non-cytotoxic bioconjugates by linking specifications to clinical relevance